Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether or not the medication that blocks the
effects of the hormone progesterone (CDB-4124 or Proellex) will decrease the growth rate of
breast cancer cells as compared to a placebo. CDB-4124 (also called Proellex) is a medication
that works against the hormone, progesterone. The researchers in this study would like to
compare changes in breast cancer cells of women who have taken CDB-4124 prior to surgery to
those from women who have taken a placebo pill prior to surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborators:
Breast Cancer Research Foundation Repros Therapeutics Inc.